Efficacy and safety of Jentadueto® (linagliptin plus metformin).
about
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.A review of gliptins for 2014.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.New fixed dose chemical combinations: the way forward for better diabetes type II management?
P2860
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
@en
type
label
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
@en
prefLabel
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
@en
P2860
P1476
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
@en
P2093
André J Scheen
P2860
P304
P356
10.1517/14740338.2013.771631
P407
P577
2013-03-01T00:00:00Z